78 research outputs found
Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΊΠ°Π»ΡΡΠΈΠΉΡΠΎΡΡΠ°ΡΠ½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡΠΌΠΈ Π±Π΅Π»ΠΊΠΎΠ²ΠΎΠΉ ΠΏΡΠΈΡΠΎΠ΄Ρ
Recent approaches to the calcium phosphate (CaP) materials functionalization with drugs and biomolecules have been actively developed for bone defect reconstruction. However, the current techniques are low efficient in context of drug incorporation and non-controlled release from the materials. Eventually, continuous therapeutic effect in bone defect area couldnβt be achieved. The aim of this work was to develop an effective method for biologically active molecules incorporation onto the surface of CΠ°P materials, and to study the dynamics of its release. Octacalcium phosphate (OCP), Ξ²-tricalcium phosphate (Ξ²-TCP) and Ξ²-tricalcium phosphate with biomimetic calcium phosphate layer (Ξ²-TCPmod.) were used as ceramic bioactive carriers. Bovine serum albumin (BSA) was used as a model compounds. BSA incorporation on the ceramics surface was performed by biomimetic co-precipitation from several buffer solutions containing the incorporated compound. The efficiency of biomolecules incorporation was evaluated by measuring BSA concentrations in solutions before and after materials incubation. The release of the incorporated molecules from the materials was investigated for 6 days. The structure and composition of the obtained materials were studied by application of XRD, FTIR, SEM, BET methods. It was shown that the OCP specific surface (surface area, (SBET)) was almost in 12 times higher than SBET of Ξ²-TCP. By using biomimetic approach the increase of Ξ²-TCP surface area in 1.6 times was achieved; this enhanced protein incorporation more than 3 times. The BSA biomimetic co-precipitation together with CaP on the OCP surface proved to be more effective than its adsorption from salt free solutions. The study of BSA release revealed that only 45% of loaded albumin released during 6 days of observation. Therefore, the effective method of CaP functionalization was developed. Based on biomolecules incorporation by biomimetic co-precipitation from CaP solutions, it provided a low rate of its release.Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π΅ Π²ΡΠ΅ΠΌΡ Π°ΠΊΡΠΈΠ²Π½ΠΎ ΡΠ°Π·ΡΠ°Π±Π°ΡΡΠ²Π°ΡΡΡΡ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΊΠ°Π»ΡΡΠΈΠΉΡΠΎΡΡΠ°ΡΠ½ΡΡ
(ΠΠ€) ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡΠΌΠΈ Ρ ΡΠ΅Π»ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΈΡ
Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΏΠ»Π°ΡΡΠΎΡΠΌΡ Π΄Π»Ρ Π°Π΄ΡΠ΅ΡΠ½ΠΎΠΉ Π΄ΠΎΡΡΠ°Π²ΠΊΠΈ Π² Π·ΠΎΠ½Ρ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ Π΄Π΅ΡΠ΅ΠΊΡΠ°. ΠΠ΄Π½Π°ΠΊΠΎ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΡ ΠΈΠ½ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΠΈ ΠΈ Π½Π΅ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠΎΡΠΎΡΡΡΡ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΈΠ· ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ², Π½Π΅ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠ΅ΠΉ ΠΏΠΎΡΡΠΎΡΠ½Π½ΡΠΉ ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ Π² ΠΎΠ±Π»Π°ΡΡΠΈ Π΄Π΅ΡΠ΅ΠΊΡΠ°. Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΡΠ°Π»Π° ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠΏΠΎΡΠΎΠ±Π° ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΠ€ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΈΡ
Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ. Π ΡΠ°Π±ΠΎΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π³ΡΠ°Π½ΡΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΠ€ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΎΠΊΡΠ°ΠΊΠ°Π»ΡΡΠΈΠ΅Π²ΡΠΉ ΡΠΎΡΡΠ°Ρ (ΠΠΠ€), Ξ²-ΡΡΠΈΠΊΠ°Π»ΡΡΠΈΠ΅Π²ΡΠΉ ΡΠΎΡΡΠ°Ρ (Ξ²-Π’ΠΠ€) ΠΈ Ξ²-Π’ΠΠ€ Ρ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΠ€ ΡΠ»ΠΎΠ΅ΠΌ Π½Π° ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ (Ξ²-Π’ΠΠ€ΠΌΠΎΠ΄.), Π° Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠΎΠ΄Π΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡ - Π±ΡΡΠΈΠΉ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΠΉ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ (BSA). ΠΠ½ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΡ BSA Π½Π° ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡ ΠΊΠ΅ΡΠ°ΠΌΠΈΠΊΠΈ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ Ρ Π±ΠΈΠΎΠΌΠΈΠΌΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΠ€ Π±ΡΡΠ΅ΡΠ½ΡΡ
ΡΠ°ΡΡΠ²ΠΎΡΠΎΠ², ΡΠΎΠ΄Π΅ΡΠΆΠ°ΡΠΈΡ
ΠΈΠ½ΠΊΠΎΡΠΏΠΎΡΠΈΡΡΠ΅ΠΌΠΎΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅. ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈΠ½ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΠΈ BSA ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ, ΠΈΠ·ΠΌΠ΅ΡΡΡ Π΅Π³ΠΎ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π² ΡΠ°ΡΡΠ²ΠΎΡΠ°Ρ
Π΄ΠΎ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΈΠ½ΠΊΡΠ±Π°ΡΠΈΠΈ Ρ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°ΠΌΠΈ. ΠΠΈΠ½Π°ΠΌΠΈΠΊΡ Π²ΡΡ
ΠΎΠ΄Π° BSA ΠΈΠ· ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 6 ΡΡΡΠΎΠΊ. ΠΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡ ΠΈ ΡΡΡΡΠΊΡΡΡΡ ΠΠ€ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ²: ΡΠΊΠ°Π½ΠΈΡΡΡΡΠ΅ΠΉ ΡΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΠΈ, ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΡΠ°Π·ΠΎΠ²ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, ΠΠ-Π€ΡΡΡΠ΅ ΡΠΏΠ΅ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°, Π½ΠΈΠ·ΠΊΠΎΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΠ½ΠΎΠΉ Π°Π΄ΡΠΎΡΠ±ΡΠΈΠΈ Π°Π·ΠΎΡΠ°. Π ΡΠ°Π±ΠΎΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ΄Π΅Π»ΡΠ½Π°Ρ ΠΏΠ»ΠΎΡΠ°Π΄Ρ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ (SΡΠ΄.) ΠΠΠ€ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5.9 ΠΌ2/Π³, Ξ²-Π’ΠΠ€ β 0.5 ΠΌ2/Π³. ΠΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Ξ²-Π’ΠΠ€ ΠΏΡΠΈΠ²Π΅Π»Π° ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ SΡΠ΄. Π² 1.6 ΡΠ°Π· ΠΈ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Π²ΡΡΡΠΎΠ΅Π½Π½ΠΎΠ³ΠΎ BSA Π½Π° Π΅Π³ΠΎ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΡ Π² 3 ΡΠ°Π·Π°. Π‘ΠΎΠ²ΠΌΠ΅ΡΡΠ½Π°Ρ ΠΏΡΠ΅ΡΠΈΠΏΠΈΡΠ°ΡΠΈΡ BSA ΠΈ ΡΠΎΡΡΠ°ΡΠΎΠ² ΠΊΠ°Π»ΡΡΠΈΡ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ Π±ΠΈΠΎΠΌΠΈΠΌΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΡ Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π΅Π΅ Π°Π΄ΡΠΎΡΠ±ΡΠΈΠΈ BSA Π±Π΅Π· ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠ€ ΡΠ°ΡΡΠ²ΠΎΡΠΎΠ². ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ BSA ΠΈΠ· ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΠΠ€ Π²ΡΡΠ²ΠΈΠ»ΠΎ, ΡΡΠΎ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 6 ΡΡΡΠΎΠΊ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π°Π΅ΡΡΡ 45% Π²ΡΡΡΠΎΠ΅Π½Π½ΠΎΠ³ΠΎ Π² ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» Π±Π΅Π»ΠΊΠ°. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π±ΡΠ» ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΠΌΠ΅ΡΠΎΠ΄ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΠ€ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ², ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠΉ Π½Π° ΠΈΠ½ΠΊΠΎΡΠΏΠΎΡΠ°ΡΠΈΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎ Ρ Π±ΠΈΠΎΠΌΠΈΠΌΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΎΡΠ°ΠΆΠ΄Π΅Π½ΠΈΠ΅ΠΌ ΠΈΠ· ΠΊΠ°Π»ΡΡΠΈΠΉ- ΡΠΎΡΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° ΠΈ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠΈΠΉ Π½ΠΈΠ·ΠΊΡΡ ΡΠΊΠΎΡΠΎΡΡΡ ΠΈΡ
Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ
ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ ΠΈ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΡ (Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ) Π±ΠΎΡΠΎΠ΄Π°Π²ΠΎΠΊ
Background: Cervical cancer and genital warts (GWs) are some of the most common manifestations of human papillomavirus infection (HPV). These lesions cause significant damage to the reproductive health of the population, which leads to increased attention to the prevention of HPV infection among various population groups.
Aims: To determine the clinical and epidemiological features of the HPV manifestations by the example of cervical cancer and genital warts.
Methods: A retrospective analysis of anamnestic information of 115 women with an established diagnosis of cervical cancer and 177 patients with an established diagnosis of GWs was performed. The clinical and epidemiological characteristics of patients with diagnoses of GWs and cervical cancer were based on the development of outpatient admission cards and inpatient histories, as well as test data for HPV.
Results: HPV 16 was the most common HPV type among patients with GWs and cervical cancer β it was detected in 37.6% of cases. Also the most frequently encountered: HPV 6/18/11/31/51/52. In 43.2% cases of HPV detection, two or more types were detected at once, the most common combinations: HPV16 and HPV18, HPV6 and HPV16, HPV6 and HPV11. Analysis of the frequency of screening for cervical cancer and visits to the gynecologist for 5 years before establishing the diagnosis showed that among those who did not screen for cervical cancer, the risk of diagnosing stage IIIV was 5.2 times higher than among individuals who underwent cervical screening 2 years ago, or once a year for the last five years. Among patients with GWs who had 2 or more sexual partners for 1 year, 13.5% of patients regularly used barrier contraception methods (condoms) during sexual contact, not regularly β 61.5%, did not use them at all β 25.0%.
Conclusions: Identifying the clinical and epidemiological features of HPV infection should contribute to the development of new and optimize existing prevention programs for a wide range of HPV-associated diseases.ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅. Π Π°ΠΊ ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ (Π Π¨Π) ΠΈ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΠ΅ (Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅) Π±ΠΎΡΠΎΠ΄Π°Π²ΠΊΠΈ ΡΠ²Π»ΡΡΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΠ°Π½Π½ΡΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π½Π°Π½ΠΎΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΡΠ΅ΡΠ± ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠΌΡ Π·Π΄ΠΎΡΠΎΠ²ΡΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ, ΡΡΠΎ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°Π΅Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΠΊ Π²ΠΎΠΏΡΠΎΡΠ°ΠΌ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΡΠ΅Π΄ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΡΡΠΏΠΏ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ.
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°ΠΊΠ° ΡΠ΅ΠΉΠΊΠΈ ΠΌΠ°ΡΠΊΠΈ ΠΈ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΡ
(Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
) Π±ΠΎΡΠΎΠ΄Π°Π²ΠΎΠΊ.
ΠΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅; ΠΎΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π°ΠΌΠΈ Π Π¨Π ΠΈ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΡ
(Π²Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
) Π±ΠΎΡΠΎΠ΄Π°Π²ΠΎΠΊ, ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΠ΅ΡΡ Π·Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΡΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ 2015 ΠΏΠΎ 2018 Π³. ΠΠ°Π½Π½ΡΠ΅ ΠΏΠΎΠ»ΡΡΠ΅Π½Ρ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ±ΠΎΡΠ° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΠΊΠ°ΡΡ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ (ΡΠΎΡΠΌΠ° 003/Ρ) ΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΠΊΠ°ΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°, ΠΏΠΎΠ»ΡΡΠ°ΡΡΠ΅Π³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΡΡ ΠΏΠΎΠΌΠΎΡΡ Π² Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
(ΡΠΎΡΠΌΠ° 025/Ρ). ΠΠ΅ΡΠΎΠ΄Ρ Π°Π½Π°Π»ΠΈΠ·Π° ΠΈ ΠΎΠ±ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π° β Π°Π½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΡΠ°ΠΌΠΊΠ°Ρ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ 292 ΠΊΠ°ΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΡ
ΡΡ Π·Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΡΡ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ β Π² 37,6% ΡΠ»ΡΡΠ°Π΅Π² β Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΠΌΠΈ Π±ΠΎΡΠΎΠ΄Π°Π²ΠΊΠ°ΠΌΠΈ ΠΈ Π Π¨Π ΠΏΡΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π²ΡΡΠ²Π»ΡΠ»ΡΡ Π²ΠΈΡΡΡ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (ΠΠΠ§) 16-Π³ΠΎ ΡΠΈΠΏΠ°. Π’Π°ΠΊΠΆΠ΅ ΡΠ°ΡΡΠΎ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ ΠΠΠ§ 6/18/11/31/51/52. Π 43,2% ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈΡΡ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π΄Π²Π° ΠΈ Π±ΠΎΠ»Π΅Π΅ ΡΠΈΠΏΠΎΠ² ΠΠΠ§, ΠΏΡΠΈ ΡΡΠΎΠΌ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΠΌΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΡΠΌΠΈ Π±ΡΠ»ΠΈ ΠΠΠ§16 ΠΈ ΠΠΠ§18, ΠΠΠ§6 ΠΈ ΠΠΠ§16, ΠΠΠ§6 ΠΈ ΠΠΠ§11. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠ°ΡΡΠΎΡΡ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° Π½Π° Π Π¨Π ΠΈ ΠΏΠΎΡΠ΅ΡΠ΅Π½ΠΈΡ Π²ΡΠ°ΡΠ°-Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³Π° Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 5 Π»Π΅Ρ Π΄ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ ΡΡΠ΅Π΄ΠΈ Π»ΠΈΡ, Π½Π΅ ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠ²ΡΠΈΡ
ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ Π½Π° Π Π¨Π, ΠΈΠ»ΠΈ ΠΏΡΠΎΡΠ΅Π΄ΡΠΈΡ
Π΅Π³ΠΎ ΠΏΡΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΡΠΈΡΠΊ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° Π½Π° IIIV ΡΡΠ°Π΄ΠΈΠΈ Π±ΡΠ» Π² 5,2 ΡΠ°Π·Π° Π²ΡΡΠ΅, ΡΠ΅ΠΌ ΡΡΠ΅Π΄ΠΈ Π»ΠΈΡ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠΎΡ
ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠ΅ΡΠ²ΠΈΠΊΠ°Π»ΡΠ½ΡΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ 2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ ΠΈΠ»ΠΈ 1 ΡΠ°Π· Π² Π³ΠΎΠ΄ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
5 Π»Π΅Ρ. Π‘ΡΠ΅Π΄ΠΈ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π°Π½ΠΎΠ³Π΅Π½ΠΈΡΠ°Π»ΡΠ½ΡΠΌΠΈ Π±ΠΎΡΠΎΠ΄Π°Π²ΠΊΠ°ΠΌΠΈ, ΠΈΠΌΠ΅Π²ΡΠΈΡ
ΠΏΠΎ Π΄Π²Π° ΠΈ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»ΠΎΠ²ΡΡ
ΠΏΠ°ΡΡΠ½Π΅ΡΠ° Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 1 Π³ΠΎΠ΄Π°, ΠΎ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π±Π°ΡΡΠ΅ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΡΠ°ΡΠ΅ΠΏΡΠΈΠΈ (ΠΏΡΠ΅Π·Π΅ΡΠ²Π°ΡΠΈΠ²ΠΎΠ²) ΠΏΡΠΈ ΠΏΠΎΠ»ΠΎΠ²ΠΎΠΌ ΠΊΠΎΠ½ΡΠ°ΠΊΡΠ΅ ΡΠΎΠΎΠ±ΡΠΈΠ»ΠΈ 13,5%, ΠΎ Π½Π΅ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠΌ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ β 61,5%; 25,0% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΠΎΠΎΠ±ΡΠ΅ Π½Π΅ Π·Π°Π΄ΡΠΌΡΠ²Π°Π»ΠΈΡΡ ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π°Ρ
ΠΏΡΠ΅Π΄ΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ.
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΏΠ°ΠΏΠΈΠ»Π»ΠΎΠΌΠ°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π΄ΠΎΠ»ΠΆΠ½ΠΎ ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΠΎΠ²Π°ΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π½ΠΎΠ²ΡΡ
ΠΈ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΡ
ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠΈΡΠΎΠΊΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΠΠΠ§-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
Impact of the covid-19 pandemic on the oncological practice
Detailed, systematic review of the world literature data, including all aspects that reflect the impact of the COVID-19 pandemic on the oncological practice was conducted. The information sources were taken from Pubmed, MedLine, Scopus, Web of Science, and RSCI systems. The data from retrospective and prospective clinical trials have been analyzed. This review presents current data on the impact of COVID-19 on cancer patients, mortality and prognosis of cancer patients infected with COVID-19, treatment options for COVID-19, as well as the case report of the cancer patient with rare atypical COVID-19 course of disease. To date, the groups of increased risk of being infected with a new coronavirus have been identified. These groups include cancer patients. Despite the pandemic, treatment of cancer patients must be continued, since the presence of a tumor process does not allow the therapy to be delayed. The world cancer community is actively continuing to develop recommendations for optimal management of cancer patients in the context of the pandemic. The most relevant of them are described in this article. Β© 2020, Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved
Breast cancer associated with CHEK2 mutation carriage
The paper presents clinical cases in which the patients were diagnosed with breast cancer (BC) associated with mutations in the CHEK2 gene. Objective. To investigate the characteristics of treatment and prevention in patients with BC associated with CHEK2 mutation carriage. Subjects and methods. In 2016-2017, the P.A. Herzen Moscow Oncology Research Institute treated three patients diagnosed with BC associated with CHEK2 mutation carriage. Two cases underwent preventive surgery: prophylactic subcutaneous mastectomy with single-stage reconstruction in one case and prophylactic bilateral tubo-ovariectomy in the other. A further follow-up of these patients and their relatives will be able to draw conclusions about the correctness of preventive surgery policy. Results. In all the three clinical cases, the patients were diagnosed with germline missense I157T mutation (p.I1e157Thr) in exon 3 of the CHEK 2 gene, which results in amino acid substitution (isoleucine to threonine at codon 470 β c.470T>C) in a heterozygous state. The volume of surgical interventions for BC, preventive surgery on the breast and ovaries in our patients was decided individually based on their clinical data. Genetic examination of their relatives is needed for primary prevention of BC. Conclusion. There is a need for further investigations in patients with BRCA1, 2, CHEK 2 mutations, as there will be a growing number of patients with mutations in these genes due to a larger number of genetic laboratories. Knowing the characteristics of inheritance and development of hereditary BC, it is necessary to elaborate surgical treatment policy for these patients, algorithms for follow-up of the patients, and an algorithm for examination and prevention of BC among their relatives. Β© Bionika Media Ltd
Breast cancer associated with CHEK2 mutation carriage
The paper presents clinical cases in which the patients were diagnosed with breast cancer (BC) associated with mutations in the CHEK2 gene. Objective. To investigate the characteristics of treatment and prevention in patients with BC associated with CHEK2 mutation carriage. Subjects and methods. In 2016-2017, the P.A. Herzen Moscow Oncology Research Institute treated three patients diagnosed with BC associated with CHEK2 mutation carriage. Two cases underwent preventive surgery: prophylactic subcutaneous mastectomy with single-stage reconstruction in one case and prophylactic bilateral tubo-ovariectomy in the other. A further follow-up of these patients and their relatives will be able to draw conclusions about the correctness of preventive surgery policy. Results. In all the three clinical cases, the patients were diagnosed with germline missense I157T mutation (p.I1e157Thr) in exon 3 of the CHEK 2 gene, which results in amino acid substitution (isoleucine to threonine at codon 470 β c.470T>C) in a heterozygous state. The volume of surgical interventions for BC, preventive surgery on the breast and ovaries in our patients was decided individually based on their clinical data. Genetic examination of their relatives is needed for primary prevention of BC. Conclusion. There is a need for further investigations in patients with BRCA1, 2, CHEK 2 mutations, as there will be a growing number of patients with mutations in these genes due to a larger number of genetic laboratories. Knowing the characteristics of inheritance and development of hereditary BC, it is necessary to elaborate surgical treatment policy for these patients, algorithms for follow-up of the patients, and an algorithm for examination and prevention of BC among their relatives. Β© Bionika Media Ltd
Π’Π΅ΡΠ°ΠΏΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΡΠ°Π΄ΠΈΠΉ-223 Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΊΠΎΡΡΠ½ΡΠΌΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ ΠΊΠ°ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎ-ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
The development of resistance to endocrine therapy and the tumor progression in patients with prostate cancer are associated with an unfavourable prognosis. The article presents a review of clinical trials of efficacy and safety, as well as the experience in using radioisotope radium-223 chloride in clinical practice in patients with castration-resistant prostate cancer with bone metastases without visceral metastases. It was shown that radium-223 chloride therapy in this category of patients leads to an increase in overall survival and time to the development of bone complications, and is characterized by good tolerability.Π Π°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π°ΡΡΠΎΡΠΈΠΈΡΡΡΡΡΡ Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΠ±Π·ΠΎΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΡΡΠ° ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ ΡΠ°Π΄ΠΈΠΎΠΈΠ·ΠΎΡΠΎΠΏΠ½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΠ°Π΄ΠΈΡ-223 Ρ
Π»ΠΎΡΠΈΠ΄Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΊΠΎΡΡΠ½ΡΠΌΠΈ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·Π°ΠΌΠΈ ΠΏΡΠΈ ΠΊΠ°ΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎ-ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π±Π΅Π· Π²ΠΈΡΡΠ΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ². ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ°Π΄ΠΈΡ-223 Ρ
Π»ΠΎΡΠΈΠ΄ΠΎΠΌ Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΈ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΊΠΎΡΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ Ρ
ΠΎΡΠΎΡΠ΅ΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡΡ
Modern trends in the breast cancer conserving surgery and oncoplastic breast surgery
Introduction: The highest priority for modern clinical oncology is functionally-sparing and organ-conserving treatment. In Russia, breast cancer (BC), among all malignant tumors, accounted for 21.1 % of women in 2017. Oncoplastic radical resections (OPS-BCS = oncoplastic surgery β breast conserving surgery) have been widely used. This term means resection of the breast for cancer using plastic surgery to restore the shape of the breast, in most cases with one-stage correction of the contralateral breast. Purpose: It was the creation of various techniques of oncoplastic breast surgery, applicable for the appropriate localization of breast cancer and the evaluation of surgical, oncological and aesthetic results. Methods: From 2013 to 2017, in the P.A. Hertsen Moscow Oncology Research Center, organ-conserving surgery were performed in 570 patients with BC with an average age of 54.2. Stage 0 was diagnosed in 4.6 %, I β 5.9 %, IIA β 28.7 %, IIB β 6 %, IIIA β 5.1 %, IIIC β 3.3 %, IIIB β 0.2 %, IV β 0.2 %. Radical resection in the standard version was performed in 290 patients with breast cancer, oncoplastic breast surgery in various modifications β in 280. All patients after the organ-conserving surgical treatment received radiation therapy. Patients received chemotherapy, targeted therapy and hormone therapy according to the indications in depending the disease stage and the immunohistochemical type of the tumor. Results: After an urgent and planned morphological study positive margins of resection were revealed in 10 patients, which required reresection of the edges to a negative state of them in case of an urgent intraoperative response and mastectomy β in case of a planned response. Within 4 years, local recurrences were detected in 4 patients (0.7 %), which required a mastectomy with a one-stage reconstruction. In 1 patient (0.2 %), the disease progressed as metastases to the lung β in this case lobectomy and a necessary chemotherapy were conducted. Cosmetic results were defined as excellent in 70 % cases, good β 25 %, satisfactory β 5 %. Conclusion: If there are indications for organ-conserving treatment of breast cancer and the patientβs decision concerning this surgery, the patient should be offered methods of oncoplastic surgery for the prevention of psychological and emotional stress, effective rehabilitation, and a quick return to active social life. Β© 2018 Medical Radiology and Radiation Safety. All rights reserved
- β¦